The SEC’s November 13, 2025, report reveals a subtle crescendo: General Atlantic’s stake in Pharvaris swelled to 8,031,252 shares, a figure that glows like a lantern in the twilight of the biotech sector. As of September 30, 2025, this portfolio piece was valued at $200.38 million-a testament to the company’s quiet promise.
Ethereum’s price, after some nice moves above $2,720, has found a new energy, almost as if it were in competition with Bitcoin. And like any good contestant, it gained some serious traction above the $2,850 and $2,880 resistance levels. 🔥
But wait, this is only the second such upgrade in 2025! The first, the Pectra fork in May, saw Ethereum’s price soar by a bold 29%, setting new standards for validator operations. Will Fusaka’s magic do the same for ETH? Only time-and perhaps a few market swings-will tell.
The only herald of this renewal was the ink of its quarterly earnings, cast in print and digital alike-an overture that toppled the gloom with tangible figures that shimmered like faint stars on a wintry night. Though the day of the report passed unnoticed-a still pond disturbed only slightly-the subsequent days rippled with newfound confidence, certainty burgeoning as the results sowed seeds of hope in investors’ silent hearts.
Enter Peter Brandt, the soothsayer of Wall Street, who claims traders must accept that Bitcoin’s price is doing a slow dance of decay-like a tragic Russian ballet. Miners are throwing in the towel, chatting about Bitcoin and shiny tokens while the market trembles like a failed attempt at a balalaika concerto. 🎻
According to a recent SEC filing, Praesidium sold 104,000 shares of CyberArk, effectively removing it from its portfolio. This exit occurred amid the company’s robust third-quarter performance, with revenues climbing 43% and solid growth in its cloud-based and identity security platforms. Yet, for the strategic eye, this transaction signals more than a simple loss of faith. It hints at a recalibration-an acknowledgment that even market leaders, when fully priced, become less attractive for those committed to long-term value creation.
On a November day heavy with bureaucratic solemnity, Praesidium filed its Report No. 13F dated November 14. Twenty-six weeks prior, this fund had clutched 458,000 shares of a company whose name, like a stubborn villager in Tolstoy’s Russia, clung to the past even as the world marched ahead. Shares were now reduced by 45%, the position’s value slashed by $22.8 million. By September’s end, the stake remained at 251,840 shares, valued at $23.7 million-a sum as insistent as autumn’s rain upon a windowpane.
Let’s talk about XRP. It’s clinging to the $2 mark like a desperate limpet on a particularly slippery rock. The charts are telling a story, and it’s not a happy one: lower highs, lower lows, a descending channel so clean you could probably use it to measure things. Any attempt to climb out has been met with a swift and rather dismissive slap-down. It seems the sellers are thoroughly enjoying themselves.
Both funds, in their own way, seek to grant investors a slice of the consumer staples pie. Yet, XLP, that paragon of frugality, boasts a lower expense ratio and a more concentrated portfolio, while IYK, ever the broad-minded soul, spreads its wings wider, with a smattering of healthcare and basic materials to its name. A dash of variety, one might say, though not without its price.
The ETH futures premium and the put options skew indicate that traders are hedging aggressively despite an 8% price rebound.
